George W. Kosturko

Array ( [id] => 20568466 [patent_doc_number] => 20260062387 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-05 [patent_title] => SALT-INDUCIBLE KINASE INHIBITOR COMPOUND AND PHARMACEUTICAL COMPOSITION INCLUDING THE SAME [patent_app_type] => utility [patent_app_number] => 19/383969 [patent_app_country] => US [patent_app_date] => 2025-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55062 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 18 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19383969 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20598962 [patent_doc_number] => 20260076965 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2026-03-19 [patent_title] => METHOD OF TREATING SCLC AND MANAGING THROMBOCYTOPENIA [patent_app_type] => utility [patent_app_number] => 19/336364 [patent_app_country] => US [patent_app_date] => 2025-09-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45630 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -28 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19336364 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20406343 [patent_doc_number] => 20250375452 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-12-11 [patent_title] => SOTORASIB DOSING REGIMEN [patent_app_type] => utility [patent_app_number] => 19/309299 [patent_app_country] => US [patent_app_date] => 2025-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 49 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19309299 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20715328 [patent_doc_number] => 12630562 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Piperidylurea compounds and methods of use thereof [patent_app_type] => utility [patent_app_number] => 19/290944 [patent_app_country] => US [patent_app_date] => 2025-08-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 62333 [patent_no_of_claims] => 29 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 9 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19290944 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20320031 [patent_doc_number] => 20250332119 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-10-30 [patent_title] => NOVEL ANTI-INFLAMMATORY COMPOSITION AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 19/265100 [patent_app_country] => US [patent_app_date] => 2025-07-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 2589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19265100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20465354 [patent_doc_number] => 12521383 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-13 [patent_title] => Stable pharmaceutical compositions of apixaban [patent_app_type] => utility [patent_app_number] => 19/207781 [patent_app_country] => US [patent_app_date] => 2025-05-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 12111 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19207781 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20163827 [patent_doc_number] => 20250255873 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-14 [patent_title] => RESTORING FUNCTION OF SPECIFIC MUTATIONS AFFECTING THE ACTIN DYNAMIC BY ADMINISTRATION OF SAPROPTERIN [patent_app_type] => utility [patent_app_number] => 19/182228 [patent_app_country] => US [patent_app_date] => 2025-04-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10535 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 101 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 19182228 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798889 [patent_doc_number] => 20250064814 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => FORMULATION PRODUCTION PROCESS [patent_app_type] => utility [patent_app_number] => 18/946234 [patent_app_country] => US [patent_app_date] => 2024-11-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4076 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18946234 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798900 [patent_doc_number] => 20250064825 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/943124 [patent_app_country] => US [patent_app_date] => 2024-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8007 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943124 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19798901 [patent_doc_number] => 20250064826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-27 [patent_title] => NASAL COMPOSITIONS COMPRISING ALCAFTADINE [patent_app_type] => utility [patent_app_number] => 18/943165 [patent_app_country] => US [patent_app_date] => 2024-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8004 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18943165 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19815033 [patent_doc_number] => 20250073240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-06 [patent_title] => NEW TREATMENT [patent_app_type] => utility [patent_app_number] => 18/825447 [patent_app_country] => US [patent_app_date] => 2024-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16572 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18825447 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19743925 [patent_doc_number] => 20250032490 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-30 [patent_title] => THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA [patent_app_type] => utility [patent_app_number] => 18/784478 [patent_app_country] => US [patent_app_date] => 2024-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30923 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18784478 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19541641 [patent_doc_number] => 20240358677 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-31 [patent_title] => LASOFOXIFENE TREATMENT OF AROMATASE-RESISTANT ER+ CANCER [patent_app_type] => utility [patent_app_number] => 18/764277 [patent_app_country] => US [patent_app_date] => 2024-07-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11743 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -27 [patent_words_short_claim] => 59 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18764277 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510434 [patent_doc_number] => 20240342120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => MULTIPLE MYELOMA TREATMENT [patent_app_type] => utility [patent_app_number] => 18/754044 [patent_app_country] => US [patent_app_date] => 2024-06-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1898 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 25 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18754044 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19510442 [patent_doc_number] => 20240342128 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-10-17 [patent_title] => IMMUNE MEMORY INDUCTION BY PLATINUM BASED COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/751933 [patent_app_country] => US [patent_app_date] => 2024-06-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15773 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18751933 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19447274 [patent_doc_number] => 20240307404 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-19 [patent_title] => Composition for Treatment of Muscular Disorders [patent_app_type] => utility [patent_app_number] => 18/678506 [patent_app_country] => US [patent_app_date] => 2024-05-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8423 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18678506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19845181 [patent_doc_number] => 20250090532 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-20 [patent_title] => SHP2 INHIBITOR COMPOSITIONS AND METHODS FOR TREATING CANCER [patent_app_type] => utility [patent_app_number] => 18/655511 [patent_app_country] => US [patent_app_date] => 2024-05-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51839 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 28 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18655511 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20356163 [patent_doc_number] => 12472142 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-11-18 [patent_title] => Liquid depot for non-invasive sustained delivery of agents to the eye [patent_app_type] => utility [patent_app_number] => 18/650914 [patent_app_country] => US [patent_app_date] => 2024-04-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 17 [patent_no_of_words] => 9813 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18650914 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19860639 [patent_doc_number] => 20250099425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-03-27 [patent_title] => PHARMACEUTICAL COMPOSITIONS FOR TREATING CYSTIC FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/643207 [patent_app_country] => US [patent_app_date] => 2024-04-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 55379 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18643207 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19464037 [patent_doc_number] => 20240317706 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-09-26 [patent_title] => COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/640987 [patent_app_country] => US [patent_app_date] => 2024-04-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 47869 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 14 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18640987 [rel_patent_id] =>[rel_patent_doc_number] =>)